Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.

Continued controversy surrounds the optimal empirical treatment for febrile neutropenia. New broad-spectrum beta-lactams have been introduced as single treatment, and classically, a combination of a beta-lactam with an aminoglycoside has been used.